Bimatoprost as a Treatment for Graves' Orbitopathy
Recruiting
Early Phase 1
Interventional Study
Graves Ophthalmopathy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 3 (estimated)
- Sponsor
- Johns Hopkins University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria: Graves' Ophthalmopathy with Exophthalmos/Proptosis -
Exclusion Criteria: Active Graves Disease, Currently pregnant, Taking Steroids
\-
Contacts